Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) EBT Margin (2020 - 2025)

Vivos Therapeutics has reported EBT Margin over the past 6 years, most recently at 181.85% for Q4 2025.

  • Quarterly EBT Margin fell 10540.0% to 181.85% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 121.72% through Dec 2025, down 4763.0% year-over-year, with the annual reading at 121.71% for FY2025, 4762.0% down from the prior year.
  • EBT Margin was 181.85% for Q4 2025 at Vivos Therapeutics, down from 79.61% in the prior quarter.
  • Over five years, EBT Margin peaked at 452.05% in Q4 2022 and troughed at 181.85% in Q4 2025.
  • The 5-year median for EBT Margin is 104.32% (2021), against an average of 61.4%.
  • Year-over-year, EBT Margin soared 48336bps in 2021 and then tumbled -58318bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 293.9% in 2021, then soared by 54bps to 452.05% in 2022, then plummeted by -129bps to 131.13% in 2023, then soared by 42bps to 76.45% in 2024, then tumbled by -138bps to 181.85% in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EBT Margin are 181.85% (Q4 2025), 79.61% (Q3 2025), and 131.23% (Q2 2025).